Inhibition of Maternal-to-Fetal Transfer of IgG Antibodies by FcRn Blockade in a Mouse Model of Arthrogryposis Multiplex Congenita

Ester Coutinho, MD, DPhil, Leslie Jacobson, DPhil, Anthony Shock, PhD, Bryan Smith, PhD, Anthony Vernon, PhD,* and Angela Vincent, MD, FRCPath*

Neurol Neuroimmunol Neuroinflamm 2021;8:e1011. doi:10.1212/NXI.0000000000001011

Abstract

Objective
To determine whether blocking the neonatal Fc receptor (FcRn) during gestation with an anti-FcRn monoclonal antibody (mAb) reduces transfer of pathogenic maternal antibodies in utero and decreases the likelihood of maternal antibody-mediated neonatal disease in the offspring.

Methods
Using a previously established maternal-to-fetal transfer mouse model of arthrogryposis multiplex congenita (AMC), we assessed the effect of 4470, an anti-FcRn mAb, on the transfer of total human immunoglobulin G (IgG) and specific acetylcholine receptor (AChR)-antibodies from mother to fetus, as well as its effect on the prevention of neurodevelopmental abnormalities in the offspring.

Results
Offspring of pregnant dams treated with 4470 during gestation showed a substantial reduction in total human IgG and AChR antibody levels compared with those treated with the isotype mAb control. Treatment with 4470 was also associated with a significant reduction in AMC-IgG–induced deformities (limb or spinal curve malformations) when compared with mAb control–exposed embryos and a nonsignificant increase in the percentage of fetuses showing spontaneous movements. 4470 exposure during pregnancy was not associated with changes in general parameters of maternal well-being or fetal development; indeed, male neonates showed faster weight gain and shorter time to reach developmental milestones.

Conclusions
FcRn blockade is a promising therapeutic strategy to prevent the occurrence of AMC and other human maternal autoantibody-related diseases in the offspring.
Immunoglobulin G (IgG) antibodies are transferred via the placenta from mother to fetus. This process, mediated by the neonatal Fc receptor (FcRn), protects the neonate against infectious agents. Transfer of maternal disease-associated IgG antibodies or those pathogenic to the fetus, however, can cause disease in the offspring (see reference 1 for a review). One of the best examples of these phenomena is maternal myasthenia gravis (MG) in which transfer of acetylcholine receptor (AChR) antibodies may be associated with neonatal MG. Moreover, transfer of maternal antibodies that specifically inhibit the fetal form of the AChR (fAChR), although rare, can cause lack of fetal movement in utero, resulting in arthrogryposis multiplex congenita (AMC).2 This can lead to fetal or neonatal death, as demonstrated by injecting maternal plasma or purified IgG containing fAChR antibodies into pregnant mouse dams.3

Although the symptoms of typical transient neonatal MG usually improve spontaneously, AMC and a recently described persisting myopathy in surviving children4,7 likely require treatment during development. Moreover, there is growing evidence that pathogenic maternal antibodies to neuronal antigens could cause long-lasting neurodevelopmental disorders.7,10

In addition to regulating transplacental transfer of IgG during pregnancy, FcRn also rescues IgG from intracellular degradation and is responsible for the long half-life of IgG (and pathogenic IgG autoantibodies) relative to other plasma proteins.11 Monoclonal antibodies that inhibit FcRn, such as rozanolixizumab, have been developed to treat IgG autoantibody-mediated diseases.12,13 However, there are no in vivo studies describing the use of these FcRn-inhibiting antibodies to prevent maternal-to-fetal transfer of pathogenic antibodies. Rozanolixizumab does not bind to rodent FcRn, but a surrogate monoclonal antibody (mAb), called 4470, has been produced and previously shown efficacy in mouse models of autoimmune disease.14,15

We used our previously established AMC mouse maternal-to-fetal transfer model1 to see whether inhibiting FcRn during gestation with 4470 reduces pathogenic IgG transfer in utero and decreases the likelihood of disease in the offspring.

**Methods**

**Experimental Design**

An overview of the experimental design3 is depicted in figure 1A. Briefly, Hsd:ICR (CD-1) outbred mice were purchased from a licensed breeding establishment (Envigo, Indianapolis, IN), mated in house, with pregnancy established by detection of vaginal coagulant plugs (defining day E0.5). Preparations of AChR-positive IgG were injected daily, via the intraperitoneal (IP) route between E12.5 and 17.5 (or E18.5 if dams were allowed to deliver). The treatment group further received 4470 (UCB Pharma, Brussels, Belgium, lot # PB2226) at doses between 0 and 40 mg/kg, administered via IP injection at E12.5 and E15.5. Control animals received a mouse IgG1 isotype mAb control (101.4; UCB Pharma, lot # PB3038). At E18.5, the dams were killed by CO2 anesthesia, followed by cardiac puncture for blood collection. After dissection of the fetuses, each conceptus was weighed and crown-rump length measured. The presence of resorptions, embryonic lethals, deformities and spontaneous movements were recorded. Fetuses were bled by decapitation. Human IgG and AChR Abs were measured in the dams and pooled fetal sera using a human IgG ELISA kit (Cambridge Bioscience, United Kingdom) and radioimmunoassay (RSR Ltd., Pontprennau, United Kingdom), respectively. For the study of neonatal behavioral outcomes, dams were allowed to deliver, and litters were randomly culled to 5–6 pups at postnatal day 1. Their physical and neurodevelopmental outcomes were assessed using the modified Fox battery, as previously reported.10 Details of methods are given in the e-Methods (links.lww.com/NXI/A493).

**Human Material**

Plasma exchange samples from a female patient with AChR-positive myasthenia gravis (AChR-IgG) and 2 mothers whose fetuses had AMC (AMC12,3 and AMC6)3 were used. The preparation of human IgGs was as previously described.10 The patients, purified IgG concentrations, and number of injected dams for each experiment are summarized in figure 1B. Most experiments were performed with AMC6-IgG, as the AMC1 preparation was very scarce. AMC6 had MG diagnosed after her second affected baby was terminated for lack of fetal movements. This baby at postmortem displayed hydrops, scoliosis, pectus excavation, abnormal genitalia, ascites, myositis, and CNS anomalies.3 In our previous work, transfer of AMC1 plasma produced a high proportion of dead or paralyzed pups, whereas 60% of the offspring of dams injected with AMC6 plasma were normal.3 Hence, in the mouse model, AMC6 plasma is not as pathogenic as AMC1 plasma.

Titrations of the patients’ plasmas against human AChR are shown in figure 1C. The MG AChR Ab plasma precipitated maximum α-bungarotoxin-AChR counts per minute at 1 μL,
but, as in previous studies, the apparent binding of the 2 AMC plasmas plateaued at much lower counts per minute. This is typical of AMC samples, as the antibodies bind predominantly to the fAChR (approximately 40% of the human AChR preparation) and also, to varying extents, particularly AMC1, displace the radioactive label from one of the 2 fAChR 125I-bungarotoxin/acetylcholine binding sites. As a result, fAChR antibody titers based on radioimmunoprecipitation assays often appear lower than the typical AChR antibody titers.

Standard Protocol Approvals, Registrations, and Patient Consents
Serum and plasma samples were archived with the patient’s consent and ethical approval for future research from the Central Oxford Research Ethics Committee (COREC 1702, 1988–1993, extended to 1998).

All in vivo experiments, with IgG preparations coded and investigators blinded, adhered to the ARRIVE guidelines and were performed in accordance with the United Kingdom Animals (Scientific Procedures) Act, 1986, and European Union Directive 2010/63/EU. The experiments were performed under HO license PPL 40/3581 with ethical approval granted by the King’s College London Animal Welfare and Ethical Review Body (AWERB).

Statistics
Results were analyzed by the independent samples t test (2 tailed) or by 1-way analysis of variance (ANOVA) with Bonferroni correction for multiple comparisons as appropriate. A statistically significant result was considered if $p < 0.05$. Effect sizes are given as Cohen $d$ or eta-squared ($\eta^2$). Analysis was performed in IBM SPSS statistics v27.0 (SPSS Inc., Chicago, IL). Graphs were plotted using Graph Pad prism v8 (GraphPad software, San Diego, CA). Data are presented as mean ± SEM, unless otherwise stated.

Data Availability
All data generated from this study will be shared at the request of other investigators for purposes of replicating procedures and results.
Results

Effect of FcRn Blockade on the Transfer of Human AChR Antibodies and Total IgG

The effect of different concentrations of 4470 (0, 10, 20, and 40 mg/kg) on the transfer of AChR antibodies from a patient with typical MG (binding largely to the 2 alpha subunits common to both adult and fAChRs) was tested first (figure 2A). The drug had only a suggestive effect on the antibody titers in the dams (ANOVA; p = 0.06; η² = 0.67), but reduced the antibody titer in their fetuses (ANOVA; p = 0.02; η² = 0.78), significant at 40 mg/kg after Bonferroni correction (0 vs 40 mg/kg; adjusted p = 0.035). Importantly, FcRn blockade was not associated with changes in the embryo’s survival, weight, or crown-rump length or in the dams’ gestational weight gain at the doses tested (figure e-1, links.lww.com/NXI/A493). Forty milligrams per kilogram was chosen for the main experiments.

We then tested the effects of 4470 on the transfer of human total IgG and AChR Abs using IgG preparations purified from the 2 AMC plasmas. Twelve dams were injected daily with AMCl-IgG (2 dams) or AMC6-IgG (10 dams) from E12.5 to E17.5; half were injected with 4470 (40 mg/kg) on days 12.5 and 15.5, whereas the other half received the isotype mAb control antibody. There was no reduction in IgG levels in the 4470-treated dams compared with mAb control–injected dams (p = 0.64, unpaired t test [2 tailed]; Cohen d = 0.28) but a clear reduction (∼60%; p = 0.001, unpaired t test [2 tailed]; Cohen d = 2.94) in their fetuses (figure 2B). The AChR Ab levels followed the same pattern with substantial reduction in the fetuses (∼67%; p = 0.04, unpaired t test [2 tailed]; Cohen d = 1.7), exposed to 4470, but not in the dams (p = 0.27, unpaired t test [2 tailed]; Cohen d = 0.8) (figure 2C).

Effects of FcRn Blockade on Fetal Outcomes

Fifty-three 4470-treated embryos and 79 mAb control–treated embryos (from 6 litters per treatment group) were studied at E18.5. To control for the differences in the numbers of embryos in the different litters, data are presented as percentage of affected embryos per litter. Treatment with 4470 was associated with a significant reduction in the percentage of embryos per litter with AMC-IgG–induced deformities when compared with mAb control–exposed litters (p = 0.038, independent samples t test [2 tailed]; Cohen d = 1.38). In general, the deformities observed consisted of limb or spinal curve malformations rather than embryonic lethality, which likely reflects the use of the less pathogenic patient sample (AMC6; figure 2D). Treatment with 4470 was also associated with a numerical increase in the percentage of embryos showing spontaneous movements (mainly an inspiratory breathing gasp after dissection of the embryos from the uterus) after AMC-IgG exposure, but this failed to reach statistical significance (p = 0.085, unpaired t test [2 tailed], Cohen d =
1.1; figure 2E). One 4470/AMC6-IgG–treated dam had an unusual number of empty placentas and embryos undergoing resorptions, but among all other dams, the embryos appeared normal in number, and the percentage of resorptions per litter did not statistically differ between treatment groups ($p = 0.15$, unpaired $t$ test [2 tailed]; Cohen $d = 0.9$; figure 2F).

**Effect of FcRn Blockade on Neonatal Behavior**

Recently, it has become clear that surviving children of mothers whose earlier pregnancies have been still-born or died neonatally may have facial myopathies and other defects.5 Accordingly, we examined surviving pups exposed to AMC-IgG during the neonatal period for evidence of neuromotor or other developmental dysfunction. Four dams per treatment arm were injected daily with AMC6-IgG from E12.5 to E18.5 and allowed to deliver. Unfortunately, one of the dams from the 4470-treatment group did not complete gestation (due to a technical error). Among the surviving pups (thirty-four 4470 treated and 43 mAb control treated; $p = 0.5$, unpaired $t$ test [2 tailed]), 5–6 pups per litter did not statistically differ between treatment groups ($p = 0.15$, unpaired $t$ test [2 tailed]; Cohen $d = 0.9$; figure 2F).

There were no clear differences between 4470 and mAb control mice in terms of weight gain over the first 21 days or in results of the FOX battery for neonatal development (figure e-2, links.lww.com/NXI/A493). However, in a post hoc analysis of the pups by sex, an unexpected sex difference emerged. Those male pups who were not treated with 4470 did significantly worse in terms of weight gain during the neonatal period (males: time $\times$ group $p < 0.0001$; females: time $\times$ group $p = 0.99$, repeated measures ANOVA) compared with the mAb controls, and the weight difference became more marked over time, suggesting difficulties in suckling or feeding (figure 3, A and B). The mAb control–treated males also took longer to reach criterion, statistically significant in parameters related to tasks involving cranial or limb muscles, and showing strong trends in parameters such as ear twitch (adjusted $p = 0.012$, ANOVA with Bonferroni correction), eye opening (adjusted $p = 0.056$), negative geotaxis (adjusted $p = 0.08$, ANOVA with Bonferroni correction), and open field activity (adjusted $p = 0.069$, ANOVA with Bonferroni correction) (figure 3, C, D, and F).

**Discussion**

We tested the effects of an FcRn-blocking mAb as a potential therapy in maternal antibody-mediated diseases. Using a mouse model for AMC, treatment with 4470 was associated with a significant reduction of both total human IgG and specific AChR antibodies reaching the fetal circulation. This
was associated with a reduction in the number of deformities seen in the fetuses and a trend toward an increase in spontaneous movements; moreover, surviving male offspring had better neonatal weight gain and milestones. Overall, these results demonstrate that it should be possible to inhibit IgG placental transfer to protect human babies from effects of pathogenic antibodies.

The transcytosis of maternal IgG across the human placenta and the mouse yolk sac is mediated by the FcRn.16 Besides its role in placental transport, the endothelial-expressed FcRn also protects IgG from catabolism, prolonging its half-life.17 Due to its role in IgG recycling, there has been a surge of interest in FcRn-targeting therapeutics for the treatment of autoimmune diseases.18 One recent study has investigated the use of a similar mAb on the placenta. An FcRn high-affinity mAb (M281) decreased IgG transfer in a human ex vivo placental perfusion model.18 Our study uses an in vivo system of a well-established model of maternal-to-fetal transfer of pathogenic antibodies, with excellent construct, face and predictive validity for an antibody-mediated neonatal disease.

We used a murine surrogate of rozanolixizumab, 4470, a highly specific mAb that binds to the IgG binding site on FcRn with high affinity in a pH-independent way, preventing the recycling and transcytosis of IgG.19 Importantly, 4470 does not impact on the capacity of FcRn to bind to albumin (another FcRn neurodevelopment-relevant ligand). Also of relevance, rozanolixizumab has been used in adult patients and has been found to be well tolerated with an acceptable safety profile.20,21

Important questions, however, require further research. First, the timing of IgG transfer differs in humans and rodents; in the latter, it occurs mainly during lactation. By contrast, in humans, maternal IgG is transferred from around gestational week 14, but the fAChR is replaced by the adult from around week 30, so treatment could be restricted to midgestation. Second, our study was not powered to take into consideration sex differences in neonatal outcome, but our results suggest that untreated male pups might do worse if exposed to pathogenic fAChR antibodies. The reason for this difference is not known, and at present, there are few data on the sex of surviving babies born to mothers with these antibodies. Third, the results from the model are greatly influenced by the AMC serum used, as is often the case in animal models for antibody-mediated disease. Unfortunately, the most abundant AMC sample, and thus the one used for the majority of experiments (AMC6), was previously found to be less pathogenic in animals,3 and it is therefore possible that our results are understated. A further concern relates to the risk of transient hypogammaglobulinemia of the newborn and associated risk of infections (since neonatal IgG production only starts at 6 months of age). This could apply if the FcRn blockade was required in the last trimester to prevent neonatal disease rather than midgestation. If hypogammaglobulinemia was detected in the newborn, passive immunoglobulin could be administered at birth, as is current practice in similar clinical situations. Finally, although not a statistically significant difference, the number of resorptions was higher in the treatment group. This observation was driven by a single animal who had a high number of embryos undergoing resorptions and we did not observe a difference on embryos’ survival when testing different dosages of the drug. However, this will need careful assessment in future studies.

Despite these limitations and open questions, our study supports further research into FcRn blockade as a promising therapeutic strategy to prevent disease before irreversible damage to the fetus/newborn is established. In particular, this study could have wide implications in the prevention of other maternal antibody-mediated diseases,22 neonatal lupus syndrome,23 or even forms of autism and intellectual disability with the growing evidence for pathogenic maternal antibodies to CNS antigens.7-10,24

Acknowledgment
A. Vincent thanks Prof. David Beeson for his support.

Study Funding
This study was partially funded by UCB Pharma and an MRC Centre grant (MR/N026063/1). E. Coutinho is supported by a clinical fellowship from the MRC Centre for Neurodevelopmental disorders.

Disclosure
E. Coutinho and L. Jacobson report no disclosures. A. Shock is an employee of UCB Pharma and holds stock options. B. Smith is a former employee of UCB Pharma; UCB Pharma is the manufacturer and sponsor of rozanolixizumab, an FcRn inhibitor, which is currently being investigated in clinical trials in a number of autoimmune disorders. A. Vernon reports no disclosures. A. Vincent and the University of Oxford hold patents for MuSK, LGI1, CASPR2 and VGKC-complex antibody assays, licensed to Athena Diagnostics and Euroimmun AG, not relevant to this study. Go to Neurology.org/NN for full disclosures.

Publication History
Received by Neurology: Neuroimmunology & Neuroinflammation January 24, 2021. Accepted in final form March 17, 2021.

Appendix Authors

<table>
<thead>
<tr>
<th>Name</th>
<th>Location</th>
<th>Contribution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ester Coutinho, MD, DPhil</td>
<td>Department of Basic and Clinical Neuroscience, Institute of Psychiatry, Psychology and Neuroscience, Maurice Wohl Clinical Neuroscience Institute; Medical Research Council Centre for Neurodevelopmental Disorders, King’s College London, United Kingdom</td>
<td>Drafting/revision of the manuscript for content, including medical writing for content; major role in the acquisition of data; study concept or design; and analysis or interpretation of data</td>
</tr>
</tbody>
</table>
Appendix (continued)

<table>
<thead>
<tr>
<th>Name</th>
<th>Location</th>
<th>Contribution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Leslie Jacobson, DPhil</td>
<td>Nuffield Department of Clinical Neurosciences, University of Oxford, United Kingdom</td>
<td>Major role in the acquisition of data; study concept or design; and analysis or interpretation of data</td>
</tr>
<tr>
<td>Anthony Shock, PhD</td>
<td>UCB Pharma, Slough, United Kingdom</td>
<td>Drafting/revision of the manuscript for content, including medical writing for content; study concept or design; and analysis or interpretation of data. Additional contributions: provision of FcRn and control monoclonal antibodies</td>
</tr>
<tr>
<td>Bryan Smith, PhD</td>
<td>UCB Pharma, Slough, United Kingdom</td>
<td>Drafting/revision of the manuscript for content, including medical writing for content; study concept or design; and analysis or interpretation of data. Additional contributions: provision of FcRn and control monoclonal antibodies</td>
</tr>
<tr>
<td>Anthony Vernon, PhD</td>
<td>Department of Basic and Clinical Neuroscience, Institute of Psychiatry, Psychology and Neuroscience, Maurice Wohl Clinical Neuroscience Institute; Medical Research Council Centre for Neurodevelopmental Disorders, King's College London, United Kingdom</td>
<td>Drafting/revision of the manuscript for content, including medical writing for content; major role in the acquisition of data; study concept or design; and analysis or interpretation of data</td>
</tr>
<tr>
<td>Angela Vincent, MD, FRCP</td>
<td>Nuffield Department of Clinical Neurosciences, University of Oxford, United Kingdom</td>
<td>Drafting/revision of the manuscript for content, including medical writing for content; major role in the acquisition of data; study concept or design; and analysis or interpretation of data</td>
</tr>
</tbody>
</table>

References

Inhibition of Maternal-to-Fetal Transfer of IgG Antibodies by FcRn Blockade in a Mouse Model of Arthrogryposis Multiplex Congenita
Neurol Neuroimmunol Neuroinflamm 2021;8;
DOI 10.1212/NXI.0000000000001011

This information is current as of May 27, 2021

Updated Information & Services
including high resolution figures, can be found at:
http://nn.neurology.org/content/8/4/e1011.full.html

References
This article cites 24 articles, 0 of which you can access for free at:
http://nn.neurology.org/content/8/4/e1011.full.html##ref-list-1

Citations
This article has been cited by 2 HighWire-hosted articles:
http://nn.neurology.org/content/8/4/e1011.full.html##otherarticles

Subspecialty Collections
This article, along with others on similar topics, appears in the following collection(s):
Autoimmune diseases
http://nn.neurology.org/cgi/collection/autoimmune_diseases
Developmental disorders
http://nn.neurology.org/cgi/collection/developmental_disorders
Myasthenia
http://nn.neurology.org/cgi/collection/myasthenia

Permissions & Licensing
Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at:
http://nn.neurology.org/misc/about.xhtml#permissions

Reprints
Information about ordering reprints can be found online:
http://nn.neurology.org/misc/addir.xhtml#reprintsus